ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics’ unique fibroblast cell-based approach for the potential treatment of chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany, from March 26-28, 2025. The joint meeting is an annual opportunity to showcase advances in extracellular matrix biology.

Dr. Khoja commented, “Fibroblasts are a critical component of the extracellular matrix with regenerative and immunomodulatory properties. Our presentation will detail the progress we’ve made in expanding our portfolio and targeting additional indications by leveraging the unique potential of fibroblasts.”

Details of the conference and presentations are as follows:

The German-Nordic Joint Extracellular Matrix Meeting

Presentation Title: Potential Treatment of Chronic Diseases With the Aim of Immune System Homeostasis Rather Than Depletion or Over-activation.

Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics

Location: Otto-Krayer Haus, Albertstrasse 25, Freiburg, Germany

Date and Time: Thursday, March 27, at 10:25 a.m. to 12:00 p.m. Central European Time

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

About FibroBiologics 

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com

General Inquiries: 
info@fibrobiologics.com 

Investor Relations: 
Nic Johnson 
Russo Partners 
(212) 845-4242 
fibrobiologicsIR@russopr.com 

Media Contact: 
Liz Phillips 
Russo Partners 
(347) 956-7697 
Elizabeth.phillips@russopartnersllc.com 


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.